Canakinumab (anti-IL-1β monoclonal antibody) for MDS/CMML
Current understanding
To be populated as evidence accumulates.
Evidence log
- 2026-09-16 — Canakinumab or emavusertib for anemia in lower-risk MDS: results of the CANFIRE and LUCAS phase 2, open-label, multicenter trials.: cross-connection with canakinumab: Same agent covered by an MDS/CMML-specific page; CANFIRE result belongs on both. (novelty: 3)
- 2026-04-13 — A Phase II, Open-Label, Study of Subcutaneous Canakinumab, an Anti-IL-1β Human Monoclonal Antibody, for Patients With Low or Int-1 Risk IPSS/IPSS-R Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia: Phase II open-label trial (early-stage trial data) evaluating subcutaneous canakinumab monotherapy in low/Int-1 risk IPSS/IPSS-R MDS and CMML, representing the first dedicated clinical trial of an anti-IL-1β monoclonal antibody in these myeloid neoplasms and testing inflammatory cytokine signaling as a therapeutic target. (novelty: 3)
Open questions
Related
Contributing findings
A Phase II, Open-Label, Study of Subcutaneous Canakinumab, an Anti-IL-1β Human Monoclonal Antibody, for Patients With Low or Int-1 Risk IPSS/IPSS-R Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia
13-apr-2026
novelty 3
per-area 4
introduces